Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Johnson & Johnson : FDA Approves J&J's Drug for Tough-to-Treat Tuberculosis

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/31/2012 | 08:19pm CET

--FDA approves J&J's Sirturo but requires prominent warning label

--Drug is unlikely to be a big moneymaker but may accrue goodwill to J&J

--Fewer than 100 Americans suffer from the disease, multidrug resistant TB

(Adds details on safety risks in paragraph eight, and comments from consumer group Public Citizen and FDA official in paragraphs 13-16.)

 
   By Joseph Walker and Nathalie Tadena 
 

The U.S. Food and Drug Administration approved Johnson & Johnson's (JNJ) drug to treat a form of resistant tuberculosis that is uncommon in the U.S. but growing globally.

The drug, Sirturo, will treat patients with multidrug resistant tuberculosis, or MDR-TB, a possibly fatal disease that affects as many as 630,000 people world-wide who can't be cured with existing therapies alone. Tuberculosis is a bacterial infection that mostly involves the lungs.

Sirturo, also known as bedaquiline, is not expected to be a large moneymaker for Johnson & Johnson (JNJ), one of the world's largest health-care conglomerate, because the disease is prevalent in poorer countries unable to afford high prices for the treatment. Providing the drug, though, could help the company create goodwill among regulators, governments and patients around the world.

"The commercial opportunity is very limited," said Pamela Van Houten, a J&J spokesperson. "This is part of our commitment to advance innovative medicines that help address serious public health issues."

The company said it expects to begin selling Sirturo in the second quarter of 2013, and won't announce its sales price until then. Fewer than 100 Americans have MDR-TB, according to J&J, but FDA approval is likely to strengthen the chances for approval in regions where the disease is more prevalent, including India, China and Eastern Europe.

However, the drug's potential side effects, including an increased risk of death, has raised concerns among members of the FDA. The agency will require that a prominent warning label be placed on the drug, informing consumers that patients taking Sirturo in clinical trials saw increased rates of fatalities.

"Because the drug also carries some significant risks, doctors should make sure they use it appropriately and only in patients who don't have other treatment options," said Edward Cox, an FDA official.

About 11.4% of patients taking Sirturo died in during clinical trials, compared to 2.5% taking placebos.

The FDA granted Sirturo accelerated approval, which is a type of temporary approval for diseases that don't have viable treatment options, based on less clinical data than required for traditional drug approvals.

The accelerated approval was based on data from a pair of Phase 2 studies--one of which showed 77.6% of patients in the treatment group reaching treatment success after 24 weeks compared with 57.6% of those in the placebo group.

It is still unclear, though, whether Sirturo caused the increase death rate, said Mel Spigelman, chief executive of the Global Alliance for TB Drug Development, which is partnering with J&J to develop Sirturo in more common strains of tuberculosis.

"It looked more likely that this was just a bad coincidence," Dr. Spigelman said. "But you have to be careful, and the monitoring will have to be rigorous."

Last month, an FDA panel supported a type of early approval for J&J's experimental drug; however, panel members were divided on whether Sirturo played a role in deaths seen in clinical studies.

"A greater number of deaths in the bedaquiline arm is concerning," FDA Deputy Director of Anti-Infective Products, said in a presentation to the panel. "The role of bedaquiline in deaths where hepatoxocity and cardiac failure are contributory could not be ruled out."

The consumer group Public Citizen, which had been strongly opposed to approval, said Monday that it was disappointed in the FDA's decision.

"There were five times more deaths in the drug group than in the placebo group," said Sidney Wolfe, director of health research at Public Citizen. "I don't see how [the FDA] can be so dismissive about it."

Tuberculosis usually is treated with a combination of four drugs for at least six months, according to the National Heart, Lung and Blood Institute. Some forms of tuberculosis, however, can't be treated with currently available drugs, which the FDA has said "threatens to erode the progress made in the world-wide control of tuberculosis."

Sirturo is designed to work in a new way to treat tuberculosis and would be used with other drugs.

Shares of J&J rose 27 cents to $69.75.

Write to Joseph Walker at joseph.walker@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
02/24 JOHNSON & JOHNSON : Remarks by President Trump at Signing of Executive Order on ..
02/24 JOHNSON & JOHNSON : Fourth Talcum Powder Lawsuit Heads to Trial in Missouri Ovar..
02/24 JOHNSON & JOHNSON : ex-dividend day
02/23 JOHNSON & JOHNSON : S&P upgrades Google's owner to its second-highest ranking
02/23 JOHNSON & JOHNSON : Anti-diarrhea medication ripe for abuse by opioid addicts, a..
02/22 Genmab and J&J's cancer drug set for blockbuster sales this year
02/21 Icahn buys Bristol-Myers shares, adding to activist pressure
02/21 JOHNSON & JOHNSON : Ford Still Can Repair its Brand in South Africa but it Needs..
02/21 JOHNSON & JOHNSON : Ford still can repair its brand in South Africa but it needs..
02/20 MEDTRONIC : Global High Speed Surgical Drill Market- Medtronic, Johnson and John..
More news
Sector news : Pharmaceuticals - NEC
02/24DJSHIRE : Files 8K - Other Events
02/24DJASTRAZENECA : Hyperkalaemia Drug Clears Scientific Hurdle for European Approval
02/24DJASTRAZENECA : Gets Approval for Drug Treating Hyperkalaemia
02/24 Exclusive - Trump says Republican border tax could boost U.S. jobs
02/23DJPFIZER : Files 8K - Changes Executive Management
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
02/24 UPCOMING EVENTS : J&J And NeuroDerm Put New Delivery Routes To The Test
02/24 A Dividend Portfolio Built From The World's Best Dividend ETFs
02/24 ValueAct Capital Is Going Risk-Off. Right Or Wrong?
02/24 SYNERGY : 3 Scenarios, 1 Choice
02/24 Europe's CHMP backs expanded use of Janssen Biotech's Darzalex
Advertisement
Financials ($)
Sales 2017 74 655 M
EBIT 2017 23 131 M
Net income 2017 18 272 M
Finance 2017 22 793 M
Yield 2017 2,73%
P/E ratio 2017 18,40
P/E ratio 2018 17,25
EV / Sales 2017 4,17x
EV / Sales 2018 3,94x
Capitalization 333 891 M
More Financials
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 125 $
Spread / Average Target 2,1%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON5.63%333 891
ROCHE HOLDING LTD.5.98%210 192
PFIZER INC.4.86%207 902
NOVARTIS AG4.72%202 648
MERCK & CO., INC.11.86%182 412
SANOFI4.79%109 848
More Results